logo: 4th Gastrointestinal Cancer Conference

4th Gastrointestinal Cancer Conference

Focus on oesophageal and gastric cancer - Under the auspices of EORTC

Thursday, 15 March 2018

13.30 – 14.00 h Welcome
 
  • Florian Otto, Switzerland
  • Manfred Lutz, Germany
  • Florian Lordick, Germany

 

 

14.00 – 15.30 h

Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?


Chair: Daniela Aust (Germany)

 

14.00 - 14.25 h
  • Do we need to differentiate histologically between oesophageal and gastric adenocarcinoma? (Christoph Röcken, Germany)
14.25 - 14.50 h
  • Translating molecular subtyping into clinical practice (Pierre Laurent-Puig, France)
14.50 - 15.15 h
  • Classification of oesophago-gastric cancer: surgical facts and fiction (Paul Magnus Schneider, Switzerland)

 

 

15.30 - 16.00 h

Coffee break, poster exhibition, exhibition

 

 

16.00 – 17.45 h

Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy


Chairs: Michel Ducreux (France), Paul M. Schneider (Switzerland)

 

16.00 - 16.25 h
  • Which tumours need more treatment than just surgery? (Magnus Nilsson, Sweden)
16.25 - 16.50 h
  • What imaging is needed to select patients for neoadjuvant treatment and where are the limitations? (Angela Riddell, UK)
16.50 - 17.15 h
  • Patterns of recurrence to guide selection of multi-modal treatment? (Marcel Verheij, The Netherlands)
   
   

Friday, 16 March 2018


08.30 – 10.00 h

Session 3: Treatment Modalities for Oesophago-Gastric Cancer

Chairs: Marcel Verheij (Netherlands), Dorothea Wagner (Switzerland)

08.30 - 08.55 h
  • FLOT, MAGIC or CROSS for adenocarcinoma of the oesophagus and cardia? (Elizabeth Smyth, UK)
08.55 - 09.20 h
  • Response-adapted treatment stratification in oesophago-gastric cancer (Florian Lordick, Germany)
09.20 - 09.45 h
  • Perioperative treatment strategies and current studies to improve gastric cancer outcomes in Japan (Masanori Terashima, Japan

 

 

10.00 – 10.30 h

Coffee break, poster exhibition, exhibition

 

 

10.30 – 12.00 h

Session 4: Special situation I: Signet Ring Cell Cancer

Chairs: Eric Van Cutsem (Belgium), Radka Obermannova (Czech Republic)

10.30 - 10.55 h
  • Signet ring cell carcinoma in the stomach: histopathological definitions and response to therapy assessment – the urgent need for an international consensus (Heike Grabsch, The Netherlands)
10.55 - 11.20 h
  • Endoscopic approach to signet ring cell cancer (Stefan Seewald, Switzerland)
11.20 - 11.55 h
  • Is there a role for neoadjuvant or adjuvant chemotherapy or radiochemotherapy in signet ring cell cancer? (Antoine Adenis, France)

 

 

12.00-12.30 h

Keynote: Hereditary Gastric Cancer

Fatima Carneiro, Portugal

12.45 - 13.45 h

Industry sponsored satellite symposium

 

 

12.30 - 14.00 h Lunch break, poster exhibition, exhibition

 

 

14.00 – 15.30 h

Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer

Chair: Ulrich Güller (Switzerland)

14.00 - 14.25 h
  • Positive lavage cytology or limited peritoneal carcinomatosis during laparoscopy – what should be done? (Michel Ducreux, France)
14.25 - 14.50 h
  • Peritonectomy and HIPEC for peritoneal carcinomatosis in gastric cancer: current evidence (Franco Roviello, Italy)
14.50 - 15.15 h
  • Role of surgery in oligometastatic disease? (Stefan Mönig, Switzerland)

 

 

15.30 - 16.00 h Coffee break, poster exhibition, exhibition

 

 

16.00 – 17.30 h

Session 6: Ready for Practice?

Chairs: Markus Möhler (Germany), Stefan Mönig (Switzerland)

16.00 - 16.25 h
  • Salvage surgery for oesophageal cancer: routine or exception? (Guillaume Piessen, France)
16.25 - 16.50 h
  • Biomarker stratification: molecular tumour board (Rebecca Fitzgerald, UK)
16.50 - 17.15 h
  • Quality assurance in upper GI cancer (William Allum, UK)
   
17.30 - 17.45 h
  • EORTC Gastrointestinal Tract Cancer Group: clinical trial portfolio

    Markus Möhler, Germany

Saturday, 17 March 2018

09.00 – 12.30 h

Special session

International St. Gallen Consensus: Optimal Primary Therapy of Oesophageal and Gastric Cancer

Seeking consensus on evidence and opinions about the optimal treatment of oesophageal and gastric cancer

Chairs: Manfred Lutz (Germany) and John Zalcberg (Australia)

Secretary: Michel Ducreux (France)

 

 

10.30 – 11.00 h Coffee break

 

 

Special session (continuation):

St. Gallen gastrointestinal cancer experts’ consensus panel 2016:
Seeking consensus on evidence and opinions about optimal treatment of oesophageal and gastric cancer

 

 

12.30 h Farewell
Rorschacherstr. 150
CH-9006 St. Gallen/Switzerland
Tel. +41 (0)71 243 00 32
Fax. +41 (0)71 245 68 05